Showing results (121-130 of 155) with videos related to
Sort By:
Pageof 16
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.Annals of Translational Medicine|August 5, 2021
Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assaySimon Heeke, Jonathan Benzaquen, Audrey Vallee, et al.The Lancet. Oncology|October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.European Journal of Cancer (Oxford, England : 1990)|September 8, 2020
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trialElisabeth Quoix, Clarisse Audigier-Valette, Armelle Lavolé, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 TrialJean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2021
First-Line Afatinib plus Cetuximab for <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung StudyAlexis B Cortot, Anne Madroszyk, Etienne Giroux-Leprieur, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLCKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.Lancet (London, England)|August 12, 2011
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialElisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster, et al.Pageof 16